Phase Ib Trial of CAR-T Hepatic Artery Infusions Followed by Selective Internal Radiation Therapy (SIRT) With Yttrium-90 Sir-Spheres® for CEA-Expressing Liver Metastases

Trial Profile

Phase Ib Trial of CAR-T Hepatic Artery Infusions Followed by Selective Internal Radiation Therapy (SIRT) With Yttrium-90 Sir-Spheres® for CEA-Expressing Liver Metastases

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2018

At a glance

  • Drugs CAR-T CEA therapy (Primary) ; Interleukin-2; Yttrium-90
  • Indications Liver metastases
  • Focus Adverse reactions
  • Acronyms HITM-SIR
  • Most Recent Events

    • 15 Jun 2018 Planned End Date changed from 1 Sep 2017 to 1 Jan 2019.
    • 28 Mar 2018 According to a Sorrento Therapeutics media release, the Company expects to complete this trial in 2H 2018.
    • 10 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top